齿别谤惫测迟别驳庐 EMA Submission
Completed
We are proud to announce the successfull Marketing Authorization Application submission for our lead drug candidate, Xervyteg庐 (MaaT013) to the European Medicines Agency (EMA) for the treatment in adult patients with acute Graft-versus-Host Disease including gastro-intestinal involvement who received two prior lines of therapy.